Anlotinib
Tasigna (anlotinib) is a small molecule pharmaceutical. Anlotinib was first approved as Tasigna on 2007-11-19. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1.
| Trade Name | Tasigna |
|---|---|
| Common Name | Anlotinib |
| Indication | bcr-abl positive chronic myelogenous leukemia |
| Drug Class | Tyrosine kinase inhibitors |
